Meeting
2022 ASCO Genitourinary Cancers Symposium
Response to neoadjuvant chemotherapy in histologic variants of bladder cancer.
Authors
Caroline Viala
CHU Nantes, Nantes, France
Caroline Viala , Marie Viala
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 458)
DOI
10.1200/JCO.2022.40.6_suppl.458
Abstract #
458
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Atezolizumab with platinum and etoposide chemotherapy followed by cystectomy for patients with localized small cell neuroendocrine bladder cancer.
First Author: Jean H. Hoffman-Censits
Poster
2022 ASCO Annual Meeting
S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.
First Author: Elizabeth R. Plimack
Poster
2022 ASCO Genitourinary Cancers Symposium
A prospective phase II trial of neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of bladder.
First Author: Hongsik Kim
Poster
2022 ASCO Genitourinary Cancers Symposium
Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC).
First Author: Omar Alhalabi